. "Very low."@en . "5638-76-6"@en . "Humans and other mammals"@en . "2-[2-(Methylamino)ethyl]pyridine"@en . . "Betahistinum"@en . "Betahistine"@en . . "# \"Health Canada\":http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=76587"@en . "3-4 hours"@en . . "Symptoms of overdose (< 640 mg) include mild to moderate nausea, dry mouth, dyspepsia, abdominal pain and somnolence. More serious complications such as convulsions, pulmonary or cardiac complications, may occur with higher intentional overdoses (> 640 mg). "@en . . " "@en . "Betahistine is an antivertigo drug first used for treating vertigo assosicated with M\u00E9ni\u00E8re's disease. It is also commonly used for patients with balance disorders."@en . . "2-(beta-Methylaminoethyl)pyridine"@en . "For the reduction of episodes of vertigo association with M\u00E9ni\u00E8re's disease."@en . . . . . . . . . . . . . . . . "[2-(2-Pyridyl)ethyl]methylamine"@en . . . "approved"@en . . "N-Methyl-2-(2-pyridinyl)ethanamine"@en . . "Take with food."@en . "Jean S. Cherqui, Alain C. Djiane, \"New galenical form of administration of betahistine and its derivatives and the preparation thereof.\" U.S. Patent US4264574, issued February, 1979."@en . . . . "N-Methyl-2-pyridineethanamine"@en . . . . . . . . . "Renal"@en . . "Betahistina"@en . . . . "When given orally, betahistine is rapidly absorbed from the gastrointestinal tract."@en .